-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

339 Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi

Program: Oral and Poster Abstracts
Type: Oral
Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Novel Treatment Strategies and New Data on Old Standards for Follicular Lymphoma
Hematology Disease Topics & Pathways:
Research, Adult, Translational Research, Lymphomas, B Cell lymphoma, Diseases, Lymphoid Malignancies, Biological Processes, Molecular biology, Technology and Procedures, Study Population, Human, Measurable Residual Disease , Molecular testing
Saturday, December 7, 2024: 4:30 PM

Simone Ferrero, MD1,2, Ilaria Del Giudice3*, Sara Galimberti, MD4*, Valter Gattei, MD5, Luigi Marcheselli6*, Elisa Genuardi2*, Daniela Drandi2*, Mariapia Pironti, MD2*, Irene Dogliotti, MD1*, Aurora Maria Civita2*, Irene Della Starza, PhD3,7*, Giovanni Manfredi Assanto3*, Francesca Guerrini4*, Clara Bono4*, Riccardo Bomben, PhD5*, Carola Boccomini8*, Lucia Farina9*, Jacopo Olivieri, MD10*, Luca Arcaini, MD11*, Federica Cavallo1,2*, Filippo Ballerini12*, Gloria Margiotta Casaluci, MD13*, Vittorio Ruggero Zilioli14*, Manuela Zanni, MD15*, Gerardo Musuraca, M.D., Ph.D.16*, Anna Merli17*, Benedetta Bianchi, MD18*, Silvia Bolis, MD19*, Vincenzo Pavone, MD20*, Annalisa Chiarenza21*, Annalisa Arcari22*, Catello Califano, MD23*, Samantha Pozzi, MD24*, Massimo Massaia25, Annarita Conconi26*, Tommasina Perrone, MD27*, Donato Mannina28*, Alessandro Re, MD29*, Maria Elena Nizzoli, MD30*, Dimitri Dardanis4*, Stefano Luminari30,31 and Marco Ladetto, MD32

1Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy
2Department of Molecular Biotechnology and Health Sciences, Hematology Division, University of Torino, Torino, Italy
3Hematology, Department of Translational and Precision Medicine, Sapienza University, Roma, Italy
4Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy
5Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy
6Fondazione Italiana Linfomi, Clinical Trial Office, Modena, Italy
7AIL Roma Odv, Rome, Italy
8SC Ematologia, AOU Città della Salute e della Scienza, Torino, Italy
9SC Ematologia, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
10Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi", Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
11Department of Molecular Medicine, University of Pavia, Pavia, Italy
12IRCCS Ospedale Policlinico San Martino, Genoa, Italy
13Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
14Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, Milano, IT-MI, Italy
15Dipartimento di Medicina Traslazionale Università del Piemonte Orientale e SCDU Ematologia, Az Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
16IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
17Ospedale degli Infermi di Rimini - U.O. di Ematologia, Rimini, ITA
18Hematology, University Hospital "Ospedale di Circolo e Fondazione Macchi" - ASST Sette Laghi, Varese, Italy
19Fondazione Irccs San Gerardo, SC di Ematologia, Monza, Italy
20Hematology Unit, Azienda C. Panico, Tricase, Italy
21A.O.U. Policlinico "G. Rodolico-S.Marco", Catania, U.O.C. Ematologia, Catania, Italy
22UO Ematologia, Ospedale Guglielmo da Saliceto, Piacenza, Italy
23EMATOLOGIA, ASL SALERNO, PRESIDIO OSPEDALIERO TORTORA PAGANI, Pagani, ITA
24Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Modena, Italy., Modena, Italy
25SC Ematologia, AO S. Croce e Carle, Cuneo, Italy
26SSD Ematologia, Nuovo Ospedale degli Infermi, Biella, Italy
27Department of Precision and Regenerative Medicine and Ionian Area, Unit of Hematology with Transplantation, Bari, Italy
28UOC di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera Papardo, Messina, Messina, Italy
29Lymphoma Unit, Division of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
30Hematology, Azienda Unità Sanitaria Locale IRCCS of Reggio Emilia, Reggio Emilia, Italy
31Surgical, Medical and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Reggio Emilia, Italy
32Department of Translational Medicine, Università del Piemonte Orientale ed SCDU Ematologia AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Piedmont, Italy

Introduction. Minimal residual disease (MRD) analysis has been largely used in follicular lymphoma (FL) for outcome prediction. However, despite the broad employment of rituximab maintenance for long-term disease control, there are few published data describing the prognostic impact of MRD monitoring during anti-CD20 maintenance or pre-emptive rituximab strategies. Therefore, we performed a wide and comprehensive MRD analysis at several predefined time points in the phase III, “FOLL12” trial [Luminari JCO 2022], sponsored by the Fondazione Italiana Linfomi (FIL). This is the largest MRD-driven clinical trial ever conducted in FL comparing conventional rituximab maintenance (after R-CHOP or BR) vs a combined PET/MRD response-adapted post-induction approach. We here present for the first time the MRD results stratified by post-induction treatment arm. Methods. Peripheral blood (PB) and bone marrow (BM) samples were centralized at the four Italian Euro-MRD certified laboratories of the FIL MRD Network. MRD was assessed with consensus primers on IGH::BCL2 rearrangements by RQ-PCR at end of induction (EOI) and every six months thereafter during either two years rituximab maintenance (reference arm, REF) or a response-adapted approach, offering up to three cycles of four, weekly pre-emptive rituximab infusions only in case of MRD positivity (experimental arm, EXP), till month 24. Results. High MRD negativity rates were obtained at EOI in both treatment arms (REF vs EXP: 92% vs 88% p=0.255), but the MRD kinetics changed overtime during the 24 months after EOI: if 60% of patients steadily maintained MRD negativity, 27% experienced at least one MRD recurrence (being MRD negative at EOI) while 13% converted at least once from MRD positive to MRD negative; importantly, only 1% of patients steadily maintained MRD positivity overtime without clinical relapse. Actually, focusing on the time points after EOI MRD negativity rates decreased in patients of the EXP arm vs patients receiving standard rituximab maintenance, with an overall higher incidence of MRD positivity in EXP vs REF during the 2 years after EOI (relative risk of MRD positivity: 1.78, 95% CI 1.30-2.45, p<0.001). In particular, patients in REF were characterized by lower rates of MRD recurrence vs EXP (18% vs 36%, p=0.001), accounting for an overall doubled risk ratio of MRD recurrence in EXP vs REF (RR 2.03, 95%CI 1.31-3.16, p=0.001). Consequently, sustained MRD negativity at 12 months after EOI was more frequent in REF than in EXP: 90% (111/124) vs 78% (103/132), p=0.017. On the other hand, the effect of either therapeutic strategy in inducing MRD negativization in MRD positive cases was limited and similar: 14% of patients in REF vs 12% in EXP, respectively (RR 1.15, 95% CI 0.61-2.17, p=0.671). Interestingly, among MRD positive patients, no difference in MRD quantitative burden was noted between the two study arms. MRD positivity at EOI was predictive of a worse PFS in EXP arm (5-yr PFS 26% vs 61%, HR 3.05, 1.78-5.22, p<0.001), while MRD positive patients at EOI receiving maintenance rituximab were not strongly associated with adverse prognosis at present clinical update, if compared to MRD negative ones (5-yr PFS 82% vs 76% p=0.542). However, the persistence or reappearance of an MRD positive signal in PB during the second year after EOI (time points +12, +18 and +24 months) predicted a worse PFS, adjusted by treatment arms (HR 2.58, p=0.003). Finally, it is interesting to note that MRD negative patients in REF experienced a statistically significant better outcome than MRD negative patients in EXP (5-yr PFS 76% vs 61% p=0.002), highlighting that rituximab maintenance benefits also patients with sustained MRD negativity, by preserving this favorable status overtime and delaying the occurrence of clinical relapse. Conclusions. These data suggest that a regular MRD monitoring in PB is needed to better understand the complex MRD kinetics in an indolent disease such as FL, in order to early identify patients at risk of relapse. Notably, rituximab maintenance in FL improved patients’ outcome independently from their MRD status at EOI, mainly by halving the risk of MRD recurrence overtime, thus favoring a sustained MRD negativity and eventually delaying the occurrence of clinical relapse.

Disclosures: Ferrero: Beigene: Research Funding, Speakers Bureau; Gilead: Research Funding, Speakers Bureau; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Eli Lilly: Speakers Bureau; Italfarmaco: Membership on an entity's Board of Directors or advisory committees; Sandoz: Consultancy, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gentili: Speakers Bureau; EUSA Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Del Giudice: AstraZeneca: Other: educational and editorial projects; Jansenn: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Roche: Other: educational and editorial projects. Galimberti: Celgene: Honoraria; Roche: Honoraria, Other: support for attending meetings; Incyte: Honoraria; Novartis: Honoraria, Other: support for attending meetings; Jazz: Honoraria, Other: support for attending meetings; AstraZeneca: Honoraria, Other: support for attending meetings; AbbVie: Honoraria, Other: support for attending meetings; Pfizer: Honoraria; Janssen: Honoraria. Arcaini: Celgene/Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Incyte: Membership on an entity's Board of Directors or advisory committees; Verastem: Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; EUSA Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Zilioli: Kite/Gilead: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Other: Consultancy; Janssen: Speakers Bureau; Lilly: Speakers Bureau. Musuraca: SOBI: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Jansenn: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees. Conconi: Incyte: Speakers Bureau; Novartis: Honoraria; Janssen: Speakers Bureau; Abbvie: Speakers Bureau; Astra Zeneca: Speakers Bureau; Gilead: Honoraria, Speakers Bureau; Roche: Honoraria, Speakers Bureau; Beigene: Speakers Bureau. Re: Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Italfarmaco: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Sobi: Speakers Bureau. Luminari: Janssen: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Regeneron Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Kite: Membership on an entity's Board of Directors or advisory committees; Sobi: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Genmab: Membership on an entity's Board of Directors or advisory committees; BeiGene: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees. Ladetto: Beigene, Roche, Janssen, ADC Therapeutics: Consultancy, Honoraria, Research Funding, Speakers Bureau; Acerta, Sandoz: Honoraria; Regeneron: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie, Amgen, BMS, EUSA Pharma, GSK, Gentili, Gilead/Kite, Novartis, Incyte, Jazz, Lilly, Ellipses: Consultancy, Honoraria, Speakers Bureau.

*signifies non-member of ASH